An important unanswered question is whether rechallenging patients with enfortumab vedotin plus pembrolizumab after prior ICI exposure remains effective. The authors hypothesized that enfortumab ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

People who live with chronic illness often experience a tension between wanting to hide their illness and being fully known. Learn more about how to work with this conflict.

A young girl with a rare disease is preparing for a lengthy road to recovery. She’s hoping to decorate her hospital room with ...

Opening up can unlock much-needed support, but it also comes with risks. The flare-up started like all of the others: intense ...

Though some outcomes were also poorer with an interval less than a year, these were less clinically significant, experts say.

Using education and outreach to monitor beaches and promote sea turtle awareness and marine stewardship on St. John, US ...

"I am a women's health provider at a federally qualified health center and public hospital, and I've never been so scared for ...

Northwest Radon Poster Contest is underway, inviting students aged 9 to 14 from Idaho, Washington, and Oregon to create posters that raise awareness a ...

Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...